EPISODE · May 3, 2026 · 13 MIN
Novo Nordisk and OpenAI: End to End Pharma AI, the GLP One Race, and the Regulatory Crucible Ahead - May 3, 2026
from DX Today | No-Hype Podcast & News About AI & DX
Novo Nordisk and OpenAI: End to End Pharma AI, the GLP One Race, and the Regulatory Crucible Ahead - May 3, 2026 The Danish drugmaker behind Ozempic and Wegovy is integrating OpenAI's models across drug discovery, clinical trials, manufacturing, supply chain, and commercial operations, with pilots in twenty twenty six and full integration by year end. Rick Spair and Laura unpack what is real, what is theater, and what the deal signals for the rest of regulated industry. Hosted by Rick Spair and Laura. The DX Today Podcast brings you daily deep dives into the most consequential stories in the AI ecosystem. Send us fan mail: https://dxtoday.com/contact #AI #OpenAI #NovoNordisk #PharmaAI #DrugDiscovery
Embed this episode
What this episode covers
Novo Nordisk and OpenAI: End to End Pharma AI, the GLP One Race, and the Regulatory Crucible Ahead - May 3, 2026 The Danish drugmaker behind Ozempic and Wegovy is integrating OpenAI's models across drug discovery, clinical trials, manufacturing, supply chain, and commercial operations, with pilots in twenty twenty six and full integration by year end. Rick Spair and Laura unpack what is real, what is theater, and what the deal signals for the rest of regulated industry. Hosted by Rick Spair...
NOW PLAYING
Novo Nordisk and OpenAI: End to End Pharma AI, the GLP One Race, and the Regulatory Crucible Ahead - May 3, 2026
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.